FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017543334> ?p ?o ?g. }

• W2017543334 endingPage "138" @default.
• W2017543334 startingPage "130" @default.
• W2017543334 abstract "Heparanase, an endo-β-glucuronidase cleaving heparan sulfate (HS) chains at cell surfaces and in the extracellular matrix (ECM), is involved in angiogenesis, tumor progression and metastasis as well as in inflammation and kidney dysfunction. Therefore, heparanase is considered a promising therapeutic target and diagnostic marker. Recently, we have developed a simple, rapid, fully automatable fluorimetric activity assay using the synthetic sulfated pentasaccharide fondaparinux as substrate and bacterial heparinase II (HEP-II) instead of human heparanase (hHEP). The aim of this study was to evaluate this assay for inhibitor testing as well as to check whether the assay principle is applicable to measure the activity and inhibition, respectively, of the actual target enzyme hHEP. Besides the known hHEP inhibitor suramin and the antiinflammatory and antimetastatic PS3, two series of β-1,3-glucan sulfates differing in their chain length and degree of sulfation, further semisynthetic sulfated glycans, and two sulfated polysaccharides isolated from algae were included to examine structure-activity relationships. The inhibitory activity of sulfated glycans showed to be greatly dependent on both their degree of sulfation and their basic glycan structure, but independent of their molecular size. The β-1,3-glucan sulfates were superior to suramin as well as to the other glycans with similar degree of sulfations. The most active inhibitor was found to be the β-1,3-glucan sulfate PS3 (IC₅₀=0.017 μM). By using hHEP instead of HEP-II comparable results were obtained. With an IC₅₀ being about 160 times lower than that of suramin, PS3 exhibited again the strongest inhibitory effects. Inhibition of hHEP may therefore contribute to the potent antiinflammatory and antimetastatic activities of PS3 in vivo. In conclusion, the fluorimetric hHEP activity assay proved to be a simple, fully automatable tool for testing potential inhibitors. In case of HS mimetic inhibitors, the assay variant with HEP-II may provide a fast and inexpensive option for initial screening purposes." @default.
• W2017543334 created "2016-06-24" @default.
• W2017543334 creator A5005979283 @default.
• W2017543334 creator A5011460931 @default.
• W2017543334 creator A5023275823 @default.
• W2017543334 creator A5041180911 @default.
• W2017543334 date "2014-07-01" @default.
• W2017543334 modified "2023-10-18" @default.
• W2017543334 title "Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase" @default.
• W2017543334 cites W1255177158 @default.
• W2017543334 cites W1513452909 @default.
• W2017543334 cites W1953978096 @default.
• W2017543334 cites W1967205399 @default.
• W2017543334 cites W1968317675 @default.
• W2017543334 cites W1968931109 @default.
• W2017543334 cites W1975069509 @default.
• W2017543334 cites W1977254280 @default.
• W2017543334 cites W1982684154 @default.
• W2017543334 cites W1984402172 @default.
• W2017543334 cites W2000613945 @default.
• W2017543334 cites W2004273746 @default.
• W2017543334 cites W2005175992 @default.
• W2017543334 cites W2006793070 @default.
• W2017543334 cites W2010117209 @default.
• W2017543334 cites W2015962018 @default.
• W2017543334 cites W2017592559 @default.
• W2017543334 cites W2019107044 @default.
• W2017543334 cites W2020722562 @default.
• W2017543334 cites W2021036829 @default.
• W2017543334 cites W2021130116 @default.
• W2017543334 cites W2024979449 @default.
• W2017543334 cites W2038276233 @default.
• W2017543334 cites W2045131952 @default.
• W2017543334 cites W2050313801 @default.
• W2017543334 cites W2053175158 @default.
• W2017543334 cites W2066695129 @default.
• W2017543334 cites W2067993898 @default.
• W2017543334 cites W2070700334 @default.
• W2017543334 cites W2071748706 @default.
• W2017543334 cites W2073554224 @default.
• W2017543334 cites W2073968538 @default.
• W2017543334 cites W2080182849 @default.
• W2017543334 cites W2084524081 @default.
• W2017543334 cites W2089576482 @default.
• W2017543334 cites W2091502955 @default.
• W2017543334 cites W2091772842 @default.
• W2017543334 cites W2117229494 @default.
• W2017543334 cites W2118876881 @default.
• W2017543334 cites W2120967657 @default.
• W2017543334 cites W2127473093 @default.
• W2017543334 cites W2132120901 @default.
• W2017543334 cites W2135001818 @default.
• W2017543334 cites W2135044461 @default.
• W2017543334 cites W2136290915 @default.
• W2017543334 cites W2155644467 @default.
• W2017543334 cites W2160176665 @default.
• W2017543334 cites W2161616631 @default.
• W2017543334 cites W2179125273 @default.
• W2017543334 cites W274742003 @default.
• W2017543334 doi "https://doi.org/10.1016/j.jpba.2014.02.021" @default.
• W2017543334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24667567" @default.
• W2017543334 hasPublicationYear "2014" @default.
• W2017543334 type Work @default.
• W2017543334 sameAs 2017543334 @default.
• W2017543334 citedByCount "8" @default.
• W2017543334 countsByYear W20175433342016 @default.
• W2017543334 countsByYear W20175433342018 @default.
• W2017543334 countsByYear W20175433342019 @default.
• W2017543334 countsByYear W20175433342020 @default.
• W2017543334 countsByYear W20175433342021 @default.
• W2017543334 countsByYear W20175433342022 @default.
• W2017543334 crossrefType "journal-article" @default.
• W2017543334 hasAuthorship W2017543334A5005979283 @default.
• W2017543334 hasAuthorship W2017543334A5011460931 @default.
• W2017543334 hasAuthorship W2017543334A5023275823 @default.
• W2017543334 hasAuthorship W2017543334A5041180911 @default.
• W2017543334 hasConcept C108625454 @default.
• W2017543334 hasConcept C153074725 @default.
• W2017543334 hasConcept C155138218 @default.
• W2017543334 hasConcept C181199279 @default.
• W2017543334 hasConcept C185592680 @default.
• W2017543334 hasConcept C206212055 @default.
• W2017543334 hasConcept C2777478136 @default.
• W2017543334 hasConcept C2778041096 @default.
• W2017543334 hasConcept C55493867 @default.
• W2017543334 hasConceptScore W2017543334C108625454 @default.
• W2017543334 hasConceptScore W2017543334C153074725 @default.
• W2017543334 hasConceptScore W2017543334C155138218 @default.
• W2017543334 hasConceptScore W2017543334C181199279 @default.
• W2017543334 hasConceptScore W2017543334C185592680 @default.
• W2017543334 hasConceptScore W2017543334C206212055 @default.
• W2017543334 hasConceptScore W2017543334C2777478136 @default.
• W2017543334 hasConceptScore W2017543334C2778041096 @default.
• W2017543334 hasConceptScore W2017543334C55493867 @default.
• W2017543334 hasLocation W20175433341 @default.
• W2017543334 hasLocation W20175433342 @default.
• W2017543334 hasOpenAccess W2017543334 @default.
• W2017543334 hasPrimaryLocation W20175433341 @default.

• next